The recent sell off in the stock market has also put a damper on the market for initial public offerings (IPO), which was finally starting to show a nascent recovery after a dismal showing in 2009. (Learn more about the IPO market, see: The Murky Waters Of The IPO Market.)
Over the last two years, the IPO market slowed dramatically, due to the fall in the stock market and risk aversion by investors. In 2007, 272 IPO deals came to market, raising $60 billion. Only 43 IPOs were priced in 2008, raising $28 billion, followed by 63 in 2009, raising an even lower $21.9 billion.

The low point was the first quarter of 2009, when only one deal was priced. Mead Johnson (NYSE:MJN), which was spun out by Bristol-Myers Squibb (NYSE:BMY), sold shares at $24 per share. That turned out to be one of the best deals in recent memory, as the stock is selling near $46, close to a 100% return in a year.

Things started to pick up toward the end of 2009. The fourth quarter saw 32 IPOs come to market, followed by seven in January, 2010.

IN PICTURES: 7 Forehead-Slapping Stock Blunders

Current Problems
The market sell off has changed the tone of the market. Terreno Realty has cut its offering size twice in the last two weeks. The company was originally scheduled to sell 15 million shares at $20 per share, but cut that to 10 million shares in January, 2010. The company is now reportedly offering 8.75 million shares, raising approximately $175 million.

Terreno Realty is a real estate investment trust (REIT) that intends to use the funds to acquire industrial properties in six coastal areas in the United States.

Many companies that filed for IPOs didn't even make it as far as Terreno Realty, as several postponed deals. Patriot Risk Management, which provides worker's compensation insurance, postponed its deal for a week, after cutting the pricing range from $12-8 per share.

Imperial Capital, an investment bank headquartered in California, shelved its IPO due to market conditions.

Current Successes
One of the few success stories so far in 2010 is Ironwood Pharmaceuticals (Nasdaq:IRWD), a biotechnology company that is developing a drug to treat irritable bowel syndrome. The company priced its deal in early February, selling 16.67 million shares at $11.25 per share, below the expected range of $14-16.

In November 2009, Ironwood Pharmaceuticals announced successful Phase III clinical trial results for Linaclotide. The company is developing the drug in partnership with Forest Labs (NYSE:FRX)

The Bottom Line
The IPO market, which started to rebound late last year as confidence returned to equity markets, may be in for a tougher road than many thought, as the IPO market gets caught up in the recent market sell off.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Budgeting

    Your Worst Financial Mistakes And Why You Made Them

    No one intends to make a financial mistake, but an unexpected disaster or poor planning could leave you in financial distress.
  2. Stock Analysis

    Is Now the Right Time to Buy Brazilian Stocks?

    Examine the current state of the economy of Brazil, and learn why there may be some reasons for investors to look for a rally in Brazilian stocks.
  3. Stock Analysis

    Will WYNN Continue to Rally?

    Wynn Resorts has experienced a rally recently. Will it remain a good bet?
  4. Stock Analysis

    Don't Be Fooled by the Market's Recent Rally

    The bulls won for a bit in early October, but will bears have the last laugh?
  5. Stock Analysis

    Will Twitter's Stock Find its Wings Soon?

    Twitter is an enigma to many investors, but its story is pretty straightforward.
  6. Investing Basics

    How to Think About Seasonality Trends

    Investors benefit when company research incorporates seasonality trends that predict relative strength and weakness throughout the calendar year.
  7. Stock Analysis

    8 Solid Utility Stocks for a Bear Market

    If you're seeking modest appreciation, generous dividend payments and resiliency, consider these eight utility stocks.
  8. Stock Analysis

    Why Phillips 66 (PSX) is a Solid Long-Term Bet

    Here's why Phillips 66 will likely remain one of the world’s largest and most profitable companies for a long time to come.
  9. Stock Analysis

    3 Resilient Oil Stocks for a Down Market

    Stuck on oil? Take a look at these six stocks—three that present risk vs. three that offer some resiliency.
  10. Economics

    Keep an Eye on These Emerging Economies

    Emerging markets have been hammered lately, but these three countries (and their large and young populations) are worth monitoring.
  1. Can a company's working capital turnover ratio be negative?

    A company's working capital turnover ratio can be negative when a company's current liabilities exceed its current assets. ... Read Full Answer >>
  2. Does working capital measure liquidity?

    Working capital is a commonly used metric, not only for a company’s liquidity but also for its operational efficiency and ... Read Full Answer >>
  3. How do I read and analyze an income statement?

    The income statement, also known as the profit and loss (P&L) statement, is the financial statement that depicts the ... Read Full Answer >>
  4. Can working capital be too high?

    A company's working capital ratio can be too high in the sense that an excessively high ratio is generally considered an ... Read Full Answer >>
  5. How do I use discounted cash flow (DCF) to value stock?

    Discounted cash flow (DCF) analysis can be a very helpful tool for analysts and investors in equity valuation. It provides ... Read Full Answer >>
  6. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!